` 300298 (Sinocare Inc) vs Shanghai Composite Comparison - Alpha Spread

300298
vs
Shanghai Composite

Over the past 12 months, has underperformed Shanghai Composite, delivering a return of -6% compared to the Shanghai Composite's 7% growth.

Stocks Performance
300298 vs Shanghai Composite

Loading

Performance Gap
300298 vs Shanghai Composite

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
300298 vs Shanghai Composite

Loading
300298
Shanghai Composite
Add Stock

Competitors Performance
Sinocare Inc vs Peers

Shanghai Composite
300298
ABT
ISRG
BSX
SYK
Add Stock

Sinocare Inc
Glance View

Market Cap
12.1B CNY
Industry
Health Care

Nestled in the heart of China's burgeoning biotech industry, Sinocare Inc. has steadily transformed itself into a powerhouse in the realm of glucose monitoring and diabetes management. Founded in 2002, the company was driven by an urgent need to address the growing epidemic of diabetes in China and beyond. As diabetes continued to exact a heavy toll both economically and medically, Sinocare sought to leverage advanced technological innovations to pioneer user-friendly and affordable monitoring solutions. By placing a firm emphasis on research and development, the company sharpened its expertise in biosensing technology, allowing it to produce a comprehensive range of glucose monitors, test strips, and related healthcare products that cater not just to hospitals but also empower individuals with diabetes to manage their conditions effectively. In its journey, Sinocare smartly diversified beyond simple diagnostics into broader health management solutions. With an eye on increasing the accessibility and functionality of their products, they pursued strategic alliances and acquisitions, notably acquiring Nipro diagnostic business (now Trividia Health) and PTS Diagnostics. These moves helped broaden Sinocare’s horizons to international markets, offering it a stronger footing in the lucrative U.S. and European markets in addition to its dominant Asian presence. Sinocare makes money through the sale of its monitoring devices and the recurring revenue stream generated by test strips and other consumables. Their integrated approach, combining product sales with digital health management services, helps in building a robust ecosystem around its core offerings. This innovative business model not only boosts their bottom line but positions Sinocare as a critical player in the global fight against diabetes, continuously driving towards a future where chronic disease management is much more convenient and effective.

Sinocare Inc Intrinsic Value
HIDDEN
Show
Back to Top